Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands

European Respiratory Journal

Volumn 46, Issue 5, 2015, Pages 1407-1416

  Mangen, Marie Josée J ^a   Rozenbaum, Mark H ^b,c   Huijts, Susanne M ^a   Van Werkhoven, Cornelis H ^a   Postma, Douwe F ^a   Atwood, Mark ^d   Van Deursen, Anna M M ^a,e,f   Van Der Ende, Arie ^g   Grobbee, Diederick E ^a,h   Sanders, Elisabeth A M ^f   Sato, Reiko ^b   Verheij, Theo J M ^a   Vissink, Conrad E ^a   Bonten, Marc J M ^a   Ardine De Wit, G A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b PFIZER INC   (United States)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d POLICY ANALYSIS INC PAI   (United States)

^e Department of Orthopaedic Surgery   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

^h Academic Contract Research Organization   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; NETHERLANDS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; SINGLE DRUG DOSE; VACCINATION; ADOLESCENT; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; MALE; MARKOV CHAIN; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; NETHERLANDS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; VACCINATION; YOUNG ADULT;

EID: 84942777589     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00325-2015     Document Type: Article

References (43)

1. van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012; 65: 17-24.
2. World Health Organization (WHO). 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec 2008; 83: 373-384.
3. Moberley S, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013; 1: CD000422.
4. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325: 1453-1460.
5. Andrews NJ, Waight PA, George RC, et al. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 2012; 30: 6802-6808.
6. Huss A, Scott P, Stuck AE, et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009; 180: 48-58.
7. Lucero MG, Dulalia VE, Nillos LT, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 2009; 4: CD004977.
8. Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372: 1114-1125.
9. French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362: 812-822.
10. Rozenbaum MH, Hak E, van der Werf TS, et al. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged?65 years in the Netherlands. Clin Ther 2010; 32: 1517-1532.
11. Rozenbaum MH, van Hoek AJ, Fleming D, et al. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ 2012; 345: e6879.
12. Weycker D, Sato R, Strutton D, et al. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged?50 years. Vaccine 2012; 30: 5437-5444.
13. Kuhlmann A, Theidel U, Pletz MW, et al. Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany. Health Econ Rev 2012; 2: 4.
14. Jiang Y, Gauthier A, Keeping S, et al. Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK. Expert Rev Pharmacoecon Outcomes Res 2014; 14: 913-927.
15. Smith KJ. Determining the cost-effectiveness of adult pneumococcal vaccination strategies. Expert Rev Pharmacoecon Outcomes Res 2014; 14: 1-4.
16. Smith KJ, Wateska AR, Nowalk MP, et al. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012; 307: 804-812.
17. Mangen MJ, Bonten MJ, de Wit GA. Rationale and design of the costs, health status and outcomes in community-acquired pneumonia (CHO-CAP) study in elderly persons hospitalized with CAP. BMC Infect Dis 2013; 13: 597.
18. Postma DF, van Werkhoven CH, van Elden LJR, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2015; 372: 1312-1323.
19. van den Broek d'Obrenan J, Verheij TJ, Numans ME, et al. Antibiotic use in Dutch primary care: relation between diagnosis, consultation and treatment. J Antimicrob Chemother 2014; 69: 1701-1707.
20. van Vugt SF, Broekhuizen BD, Lammens C, et al. Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study. BMJ 2013; 346: f2450.
21. Centraal Bureau voor de Statistiek. Bevolking; geslacht, leeftijd, burgerlijke staat en regio, 1 januari [Population; sex, age, marital status and region, January 1]. Heerlen, Statistics Netherlands (CBS), 2014. http://statline.cbs.nl/Statweb/publication/?DM=SLNL&PA=03759ned&D1=0&D2=0,19-96,118, 129&D3=0&D4=24&HDR=T&STB=G2,G3, G1&VW=T Date last accessed: December 4, 2014.
22. van Deursen AM, van Mens SP, Sanders EA, et al. Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands. Emerg Infect Dis 2012; 18: 1729-1737.
23. van Vugt SF, Verheij TJ, de Jong PA, et al. Diagnosing pneumonia in patients with acute cough: clinical judgment compared to chest radiography. Eur Respir J 2013; 42: 1076-1082.
24. Bont J, Hak E, Hoes AW, et al. Predicting death in elderly patients with community-acquired pneumonia: a prospective validation study reevaluating the CRB-65 severity assessment tool. Arch Intern Med 2008; 168: 1465-1468.
25. van Werkhoven CH, Huijts SM, Bolkenbaas M, et al. 13-valent pneumococcal conjugate vaccine efficacy is declining with old age: results from an exploratory analysis of the CAPiTA trial. ID-Week, Philadelphia, October 8-12, 2014. Abstract 1099. https://idsa.confex.com/idsa/2014/webprogram/Paper47255.html
26. Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349: 1341-1348.
27. Health Council of the Netherlands. Pneumococcal vaccine in elderly adults and risk groups. The Hague, Health Council of the Netherlands; publication no. 2003/10; 2003. www.gezondheidsraad.nl/sites/default/files/0310n.pdf Date last accessed: June 25, 2015.
28. Jansen B, Tacken M, Mulder J, et al. Monitoring vaccination rate-Dutch National Influenza Prevention Program-2012. Nijmegen, UMC St Radboud, Scientific Institute for Quality of Healthcare, 2013. www.iqhealthcare.nl/media/73940/kort-npg-monitoring-2012-def-met-isbn.pdf Date last accessed: June 25, 2015.
29. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294: 2043-2051.
30. Knol MJ, Sanders EA, Vlaminckx B, et al. Incidence of invasive pneumococcal disease in the Netherlands after introduction of 7-valent and 10-valent pneumococcal conjugate vaccination. Pneumonia 2014; 3: 0261.
31. Stolk E, Krabbe P, Busschbach J. Using the Internet to collect EQ-5D norm scores a valid alternative? In: Busschbach J, Rabin R, De Charro F, eds. 24th Scientific Plenary Meeting of the EuroQol Group-Proceedings:153-1K5. Rotterdam, EuroQol Group, 2009.
32. Lamers LM, McDonnell J, Stalmeier PF, et al. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ 2006; 15: 1121-1132.
33. Z-Index. Official Dutch Drug Prices. Den Haag, Z-Index BV, 2014. www.z-index.nl/Date last accessed: September 17, 2014.
34. SNP. Grieppreventie SNP-Declareren/opgave vaccinaties doen. Utrecht, Stichting Nationaal Programma Grieppreventie (SNP), 2014. www.snpg.nl/griepcampagne/declareren.htm Date last accessed: April 28, 2014.
35. Tan SS, Bouwmans CA, Rutten FF, et al. Update of the Dutch Manual for Costing in Economic Evaluations. Int J Technol Assess Health Care 2012; 28: 152-158.
36. CBS. Working population; numbers according to gender and other person characteristics. 2014 http://statline.cbs.nl/StatWeb/publication/?DM=SLNL&PA=71958ned&D1=0-1, 4&D2=0&D3=0, 2-11&D4=65&HDR=T&STB=G1,G2, G3& VW=T Date last accessed: August 8, 2014.
37. OECD. Exchange Rates (indicator), 2015. doi: 10.1787/037ed317-en Date last accessed: June 26, 2015.
38. Vose D. Risk Analysis: a Quantitative Guide. Chichester, John Wiley & Sons Ltd, 2000.
39. OECD. National Accounts at a Glance 2014. Paris, The Organisation for Economic Co-operation and Development (OECD). http://stats.oecd.org/index.aspx?queryid=28226 Date last accessed: June 25, 2015.
40. Tan-Torres Edejer T, Baltussen R, Adam T, et al. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva, World Health Organization, 2003. www.who.int/choice/publications/p-2003-generalised-cea.pdf
41. van de Vooren K, Duranti S, Curto A, et al. Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies. Pharmacoeconomics 2014; 32: 29-45.
42. Restrepo MI, Faverio P, Anzueto A. Long-term prognosis in community-acquired pneumonia. Curr Opin Infect Dis 2013; 26: 151-158.
43. Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015; 15: 301-309.